1. Home
  2. BEAM vs USAS Comparison

BEAM vs USAS Comparison

Compare BEAM & USAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

N/A

Current Price

$26.08

Market Cap

2.7B

Sector

Health Care

ML Signal

N/A

Logo Americas Gold and Silver Corporation no par value

USAS

Americas Gold and Silver Corporation no par value

N/A

Current Price

$8.46

Market Cap

3.2B

ML Signal

N/A

Company Overview

Basic Information
Metric
BEAM
USAS
Founded
2017
1998
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Metal Mining
Sector
Health Care
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
3.2B
IPO Year
2019
2004

Fundamental Metrics

Financial Performance
Metric
BEAM
USAS
Price
$26.08
$8.46
Analyst Decision
Buy
Strong Buy
Analyst Count
16
2
Target Price
$49.13
$4.08
AVG Volume (30 Days)
1.7M
6.3M
Earning Date
05-15-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
82.31
N/A
EPS
N/A
N/A
Revenue
$24,000.00
N/A
Revenue This Year
N/A
$26.21
Revenue Next Year
$35.80
$129.30
P/E Ratio
N/A
N/A
Revenue Growth
33.33
N/A
52 Week Low
$13.53
$0.40
52 Week High
$36.44
$10.50

Technical Indicators

Market Signals
Indicator
BEAM
USAS
Relative Strength Index (RSI) 43.87 52.06
Support Level $23.84 $6.67
Resistance Level $29.06 $8.66
Average True Range (ATR) 1.96 0.64
MACD -0.19 -0.12
Stochastic Oscillator 14.79 36.15

Price Performance

Historical Comparison
BEAM
USAS

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

About USAS Americas Gold and Silver Corporation no par value

Americas Gold And Silver Corp is a mining company engaged in the acquisition, exploration, development, and production of precious metals mineral properties in Mexico and the United States. The company's primary operating assets, which are also its reporting segments, are the Cosala operations, the Galena Complex, and Relief Canyon. It also holds interests in the San Felipe Development Project located in Sonora, Mexico. The Cosala operations segment, which derives maximum revenue, operates in Mexico, while the Galena Complex and Relief Canyon segments operate in the United States.

Share on Social Networks: